DSM-Firmenich Venturing
VC Fund
Maastricht, The Netherlands
DSM-Firmenich Venturing is a VC fund in Maastricht focused on Biotechnology and Health Care. DSM-Firmenich Venturing provides venture capital finance for startup firms.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries DSM-Firmenich Venturing invests in
Stages DSM-Firmenich Venturing invests in
Countries DSM-Firmenich Venturing invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2.7M–$6M
- Series A
- $5M–$27M
Investment Focus
Industry
- Biotechnology 5 (63%)
- Health Care 4 (50%)
- Medical 2 (25%)
- Food and Beverage 2 (25%)
- Pet 1 (13%)
Stage
- Seed 3 (38%)
- Series A 3 (38%)
- Funding Round 1 (13%)
- Venture - Series Unknown 1 (13%)
Country
- Italy 2 (25%)
- United States 2 (25%)
- Canada 1 (13%)
- Switzerland 1 (13%)
- United Kingdom 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Emmanuel Butstraen
Chief Operating Officer and President Perfumery & Beauty
|
Chief Operating Officer and President Perfumery & Beauty | Total investments: 0 | Find email | |
Ivo Lansbergen
President of Animal Nutrition and Health
|
President of Animal Nutrition and Health | Total investments: 0 | Find email | |
Jane Sinclair
Chief Legal, Regulatory, Risk & Compliance Officer
|
Chief Legal, Regulatory, Risk & Compliance Officer | Total investments: 0 | Find email | |
Mieke Van de Capelle
Chief Human Resources Officer
|
Chief Human Resources Officer | Total investments: 0 | Find email | |
Patrick Niels
President of Taste,Texture and Health
|
President of Taste,Texture and Health | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NOUS Energy
|
NOUS Energy is a foodtech startup working on developing a new era of ingredients for Food&Beverage and Nutraceutical Market. Our first product is Koncentra, a caffeine alternative that enhances cognitive and physical performance, improving memory, concentration and reflexes without causing the typical adverse effects of caffeine such as bloodpressure spikes or tachycardia, while also improving gastrointestinal well-being. A recent functional study demonstrated the effectiveness of Koncentra on cognitive function, showing benefits even superior to caffeine. We are firm believers in the link between human health and the environment’s health. With Koncentra, we estimate -60% of water waste, -80% of CO2 emissions, at full production compared to caffeine extraction from green coffee beans. Being fully committed to sustainable innovation and plan to fully upcycle all waste from Koncentra's production by 2028, creating new ingredients and products to expand our portfolio. | $2.7M / Seed / Jul 15, 2026 | |
P2 Science
|
P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These includeflavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain. | $23M / May 26, 2026 | |
Cosaic
|
Cultivated Biosciences is a Food Production Company. | $6M / Seed / Apr 21, 2026 | |
ATRO Medical
|
ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype. | $3.5M / Venture - Series Unknown / Feb 24, 2026 | |
ExoLab Italia
|
ExoLab Italia creates innovative products based on plant exosomes from organic farming for dermocosmetic, nutraceutical and life science applications. They are specialize in tailor-made consultancy services. The company provides bioavailable supplements containing the entire phytocomplex present in plants, offering a new approach to prevention andtreatment. | $5.2M / Series A / Feb 18, 2025 | |
Enhanced Medical Nutrition
|
Enhanced Medical Nutrition builds clinical nutrition products to help patients prepare better and recover faster from surgery. | $5M / Series A / Jan 14, 2025 | |
one.bio
|
BCD Bioscience is an emerging biotechnology spinout from UC Davis that creates ingredients for food and biopharmaceutical applications. The company was founded in 2019 and is headquartered in Davis, California, United States. | $27M / Series A / Dec 12, 2024 | |
Meatly
|
Meatly provides cultivated meat made specifically for pets. | Seed / Nov 11, 2024 |
Co-Investors
819 Capital Partners
1 deal together
Accelera Ventures
1 deal together
Acre Venture Partners
1 deal together
Ajinomoto
1 deal together
Alpha Edison
1 deal together
BASF Venture Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does DSM-Firmenich Venturing invest in?
DSM-Firmenich Venturing invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is DSM-Firmenich Venturing's check size?
DSM-Firmenich Venturing typically joins rounds of $2.7M–$6M at Seed and $5M–$27M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds DSM-Firmenich Venturing participates in.
How do I contact DSM-Firmenich Venturing?
Public channels for DSM-Firmenich Venturing include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at DSM-Firmenich Venturing?
The team at DSM-Firmenich Venturing includes Emmanuel Butstraen (Chief Operating Officer and President Perfumery & Beauty), Ivo Lansbergen (President of Animal Nutrition and Health) and Jane Sinclair (Chief Legal, Regulatory, Risk & Compliance Officer), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
